Tang Capital Management LLC Invests $3.78 Million in COMPASS Pathways plc (NASDAQ:CMPS)

Tang Capital Management LLC bought a new position in shares of COMPASS Pathways plc (NASDAQ:CMPS - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm bought 1,000,000 shares of the company's stock, valued at approximately $3,780,000. Tang Capital Management LLC owned 1.46% of COMPASS Pathways as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of CMPS. RTW Investments LP acquired a new stake in shares of COMPASS Pathways in the 4th quarter valued at about $11,714,000. Point72 Asset Management L.P. grew its holdings in shares of COMPASS Pathways by 15.4% during the fourth quarter. Point72 Asset Management L.P. now owns 67,999 shares of the company's stock worth $257,000 after buying an additional 9,099 shares in the last quarter. Integral Health Asset Management LLC acquired a new stake in COMPASS Pathways in the 4th quarter valued at approximately $756,000. Cubist Systematic Strategies LLC lifted its stake in COMPASS Pathways by 205.7% in the 4th quarter. Cubist Systematic Strategies LLC now owns 126,636 shares of the company's stock valued at $479,000 after acquiring an additional 85,213 shares in the last quarter. Finally, Balyasny Asset Management L.P. bought a new stake in COMPASS Pathways in the 4th quarter valued at approximately $2,458,000. 46.19% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

CMPS has been the subject of several research reports. Cantor Fitzgerald raised shares of COMPASS Pathways to a "strong-buy" rating in a research note on Tuesday, May 13th. HC Wainwright restated a "buy" rating and set a $45.00 target price on shares of COMPASS Pathways in a report on Monday, May 12th. Stifel Nicolaus initiated coverage on shares of COMPASS Pathways in a research report on Thursday, February 27th. They issued a "buy" rating and a $11.00 target price for the company. Finally, Canaccord Genuity Group lowered their price target on shares of COMPASS Pathways from $23.00 to $15.00 and set a "buy" rating on the stock in a research note on Friday, February 28th. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, COMPASS Pathways has a consensus rating of "Buy" and a consensus target price of $20.20.

COMPASS Pathways Stock Up 3.4%

Shares of NASDAQ:CMPS traded up $0.14 during trading on Friday, hitting $4.32. 625,481 shares of the company were exchanged, compared to its average volume of 1,117,802. COMPASS Pathways plc has a fifty-two week low of $2.49 and a fifty-two week high of $8.54. The stock has a market cap of $401.47 million, a price-to-earnings ratio of -1.97 and a beta of 2.27. The company has a current ratio of 8.91, a quick ratio of 8.91 and a debt-to-equity ratio of 0.15. The firm has a fifty day moving average price of $3.42 and a two-hundred day moving average price of $3.93.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.44) earnings per share for the quarter, beating the consensus estimate of ($0.47) by $0.03. As a group, research analysts anticipate that COMPASS Pathways plc will post -2.33 earnings per share for the current fiscal year.

COMPASS Pathways Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.